Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanny Al-Samkari

Showing results (1-10 of 198) with videos related to

Pageof 20
Sort By:
Seminars in Thrombosis and Hemostasis|February 28, 2022
Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for CliniciansHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|June 21, 2025
Platelet autoantibodies have been, and continue to be, clinically relevant in immune thrombocytopeniaHanny Al-Samkari
Clinical Advances in Hematology & Oncology : H&O|July 8, 2022
Pyruvate kinase deficiency: clinical expression and new therapiesHanny Al-Samkari
Blood|June 12, 2024
How I treat bleeding in hereditary hemorrhagic telangiectasiaHanny Al-Samkari
European Journal of Internal Medicine|March 22, 2026
Left atrial appendage closure for atrial fibrillation stroke prevention in hereditary hemorrhagic telangiectasia is effective and safe with simplified, time-limited antithrombotic therapyHanny Al-Samkari
Hematology. American Society of Hematology. Education Program|December 9, 2022
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problemHanny Al-Samkari
Research and Practice in Thrombosis and Haemostasis|October 27, 2025
Iron deficiency and iron deficiency anemia in inherited bleeding disorders: common, underrecognized, and undertreatedHanny Al-Samkari
BMJ Evidence-Based Medicine|December 7, 2018
Optimal anticoagulant treatment of cancer-associated venous thromboembolism remains unclearHanny Al-Samkari
Cancer|November 28, 2019
Striving for full disclosure-An intergenerational challengeHanny Al-Samkari
Blood|November 10, 2020
Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of careHanny Al-Samkari
Pageof 20

Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
Seminars in Thrombosis and Hemostasis|February 28, 2022
Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for CliniciansHanny Al-Samkari
Journal of Thrombosis and Haemostasis : JTH|June 21, 2025
Platelet autoantibodies have been, and continue to be, clinically relevant in immune thrombocytopeniaHanny Al-Samkari
Clinical Advances in Hematology & Oncology : H&O|July 8, 2022
Pyruvate kinase deficiency: clinical expression and new therapiesHanny Al-Samkari
Blood|June 12, 2024
How I treat bleeding in hereditary hemorrhagic telangiectasiaHanny Al-Samkari
European Journal of Internal Medicine|March 22, 2026
Left atrial appendage closure for atrial fibrillation stroke prevention in hereditary hemorrhagic telangiectasia is effective and safe with simplified, time-limited antithrombotic therapyHanny Al-Samkari
Hematology. American Society of Hematology. Education Program|December 9, 2022
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problemHanny Al-Samkari
Research and Practice in Thrombosis and Haemostasis|October 27, 2025
Iron deficiency and iron deficiency anemia in inherited bleeding disorders: common, underrecognized, and undertreatedHanny Al-Samkari
BMJ Evidence-Based Medicine|December 7, 2018
Optimal anticoagulant treatment of cancer-associated venous thromboembolism remains unclearHanny Al-Samkari
Cancer|November 28, 2019
Striving for full disclosure-An intergenerational challengeHanny Al-Samkari
Blood|November 10, 2020
Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of careHanny Al-Samkari
Pageof 20